Feng Xu

ORCID: 0000-0001-6888-8753
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Radiotherapy Techniques
  • RNA modifications and cancer
  • Lung Cancer Diagnosis and Treatment
  • Cancer-related molecular mechanisms research
  • Quality and Safety in Healthcare
  • Medical Imaging Techniques and Applications
  • Circular RNAs in diseases
  • Cancer-related gene regulation
  • Lung Cancer Treatments and Mutations
  • Estrogen and related hormone effects
  • Lung Cancer Research Studies
  • Management of metastatic bone disease
  • MicroRNA in disease regulation
  • Immunotherapy and Immune Responses
  • Cancer, Hypoxia, and Metabolism
  • Metal complexes synthesis and properties
  • Prostate Cancer Treatment and Research
  • Colorectal and Anal Carcinomas
  • Cancer Immunotherapy and Biomarkers
  • Anesthesia and Pain Management
  • Ovarian cancer diagnosis and treatment
  • Immune cells in cancer
  • Bioactive Compounds and Antitumor Agents
  • Epigenetics and DNA Methylation
  • RNA Research and Splicing

Nanjing Medical University
2011-2024

West China Hospital of Sichuan University
2008-2024

Sichuan University
2007-2024

First Affiliated Hospital of Anhui Medical University
2024

Xian Yang Central Hospital
2024

Second Hospital of Anhui Medical University
2024

Anhui Medical University
2024

Jiangsu Province Hospital
2023-2024

The University of Texas MD Anderson Cancer Center
2024

Shanghai University of Medicine and Health Sciences
2024

Triple-negative breast cancer (TNBC) is highly aggressive with a poor clinical prognosis and no targeted therapy. The c-Myc protein master transcription factor potential therapeutic target for TNBC. In this study, we develop PROTAC (PROteolysis TArgeting Chimera) based on TNA (threose nucleic acid) DNA that effectively targets degrades c-Myc. aptamer selected in vitro to bind the c-Myc/Max heterodimer appended E-box sequence create high-affinity, biologically stable bivalent binder. TNA-E...

10.1021/jacs.3c02619 article EN Journal of the American Chemical Society 2023-04-17

BACKGROUND:This study investigated the effects of various doses S-ketamine on depression and pain management cervical carcinoma patients with mild/moderate depression. MATERIAL AND METHODS:This randomized, double-blind, controlled included 417 who received laparoscopic modified radical hysterectomy from April 2015 to July 2018 also had symptoms based HAMD-17 scores (8~24). All were randomized into 4 groups: 1) control group, 2) racemic ketamine 3) high-dose group; 4) low-dose group. Pain was...

10.12659/msm.922028 article EN Medical Science Monitor 2020-04-27

As a component of N6-methyladenosine (m6A) "writers," KIAA1429 was reported to promote breast cancer proliferation and growth in m6A-independent manners. However, the related mechanism metastasis has not been reported. In present study, we found could significantly migration invasion cells. Then demonstrated that knockdown impede nude mice vivo. The level SNAIL expression epithelial-mesenchymal transition (EMT) progress positively with KIAA1429. Furthermore, confirmed suppression cell...

10.1016/j.omtn.2021.08.009 article EN cc-by-nc-nd Molecular Therapy — Nucleic Acids 2021-08-19

Abstract IGF2BP2 is a new identified N6‐methyladenosine (m6A) reader and associated with poor prognosis in many tumors. However, its role related mechanism breast cancer, especially triple‐negative cancer (TNBC), remains unclear. In this study, it found that highly expressed TNBC due to the lower methylation level promoter region. Functional mechanical studies displayed could promote proliferation G1/S phase transition of cell cycle via directly regulating CDK6 an m6A‐dependent manner....

10.1002/advs.202305142 article EN cc-by Advanced Science 2023-11-20

Abstract Gynaecologic and breast cancers share some similarities at the molecular level. The aims of our study are to highlight differences about IDO1, an important immune‐related gene in female cancers. NGS data from TCGA cervical squamous cell carcinoma (CESC), ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial (UCEC), carcinosarcoma (UCS) invasive (BRCA) were analysed identify features, clinically significant potential therapeutic targets IDO1. We found IDO1 was...

10.1111/jcmm.15176 article EN cc-by Journal of Cellular and Molecular Medicine 2020-03-30

The aberrant expression of circular RNAs (circRNAs) has been identified as a novel trait cancers. However, the role circRNAs in colorectal cancer (CRC) remains to be elucidated.Informatic analysis was performed identify CRC tissues and adjacent tissues. Gain- loss-of-function experiments were constructed analyze hsa_circ_001806 roles cell stemness by sphere-formation, ALDH activity, marker tumor-initiating ability assays. CCK8 viability carried out evaluate hsa_circ_0001806 viability....

10.2147/ott.s255485 article EN OncoTargets and Therapy 2020-06-01

Chemoresistance is closely related to the therapeutic effect and prognosis in breast cancer patients.Increasing evidences demonstrated that RNA binding proteins (RBPs) have notable roles regulating cell proliferation, metastasis chemotherapeutic sensitivity.RNA motif single stranded interacting protein 2 (RBMS2), an RBP, has been considered be a tumor suppressor several cancers.However, its role of doxorubicin sensitivity patients not yet fully revealed.Here, we performed cytotoxicity assay,...

10.7150/ijbs.66480 article EN cc-by-nc International Journal of Biological Sciences 2022-01-01

N6-methyladenosine (m6A) is an abundant reversible modification in eukaryotic mRNAs. Emerging evidences indicate that m6A plays a vital role tumourigenesis. As crucial reader of m6A, IGF2BP3 usually mediates the stabilisation mRNAs via m6A-dependent manner. But underlying mechanism tumourigenesis triple-negative breast cancer (TNBC) unclear.TCGA cohorts were analysed for expression and promoter methylation levels different subtypes. Colony formation, flow cytometry assays subcutaneous...

10.1002/ctm2.1427 article EN cc-by Clinical and Translational Medicine 2023-09-01

Abstract Background To evaluate the expression of EGFR and COX-2 their correlation with prognosis in NSCLC Methods The paraffin embedded tumor samples 50 patients receiving radical resection were analyzed immunohistochemically for prognostic values explored. Results positive rate protein cells was 46%, which significantly higher than its normal lung (p = 0.0234) paracancerous tissues 0.020). nodal negative 0.04). mean survival time (31 months) lower that (48 0.008,). In post-operation...

10.1186/1756-9966-30-27 article EN cc-by Journal of Experimental & Clinical Cancer Research 2011-03-07

Stanniocalcin-2 (STC2) has been proved to regulate a variety of signaling pathways including cell growth, metastasis, and therapeutic resistance. However, the role STC2 in regulation nasopharyngeal carcinoma (NPC) remains poorly understood. In this study, we investigated regulatory function on epithelial-mesenchymal transition (EMT) glycolysis traits NPC revealed underlying molecular mechanisms. We found that was highly expressed primary tissues lymph node metastatic tissues. Silencing...

10.1007/s10565-021-09600-5 article EN cc-by Cell Biology and Toxicology 2021-04-02

Abstract To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples examined by immunohistochemistry (IHC) next‐generation sequencing (NGS), MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing performed cases deleterious variants...

10.1002/ijc.35085 article EN cc-by-nc-nd International Journal of Cancer 2024-08-07

Immune evasion is not only critical for tumor initiation and progression, but also determines the efficacy of immunotherapies. Through iterative in vivo CRISPR screens with seven syngeneic models, we identified core context-dependent immune pathways across cancer types. This valuable high-confidence dataset available further understanding intrinsic immunomodulators, which may lead to discovery effective anticancer therapeutic targets. With a focus on triple-negative breast (TNBC), found that...

10.1073/pnas.2406325121 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2024-09-19

<title>Abstract</title> Breast cancer distant metastasis is known to exhibit organotropism, with triple negative breast (TNBC) subtypes also displaying organ-specific metastasis. In publicly available clinical database of TNBC, we found that luminal androgen receptor-type (LAR) TNBC had a significant tendency for bone mouse models, demonstrated receptor (AR) activation promoted LAR Using single-cell sequencing, discovered c-Myc played critical role in AR-mediated Mechanistically, AR...

10.21203/rs.3.rs-4318418/v1 preprint EN cc-by Research Square (Research Square) 2024-05-02

MicroRNAs (miRNAs) are a class of endogenous, small, non-coding RNAs that regulate gene expression by targeting mRNAs and inhibiting via translation repression or RNA degradation. Emerging evidence indicates miRNAs play crucial role in the pathogenesis human diseases, including tumor development. We profiled miRNA between mature ovarian teratoma samples matched normal tissues using microarrays, followed validation with quantitative RT-PCR (qRT-PCR). The most highly expressed were...

10.3892/ol.2011.438 article EN Oncology Letters 2011-10-12

Ovarian cancer is one of the most serious and deadly cancers for female currently no effective screening approaches have been achieved. Therefore it usually diagnosed at an advanced stage patients a poor prognosis. The development ovarian comprehensive process depending on cross-talk between various cells in tumor microenvironment immune system. Thus, immunotherapy may be revolutionized as treatment this disease. In study, we firstly identified ASS1 immunomodulatory molecule. By RNA...

10.1016/j.bbrc.2022.08.045 article EN cc-by Biochemical and Biophysical Research Communications 2022-09-19
Coming Soon ...